Ziyao Qiao, Kaihua Long, Kairu Ding, Xiaoyan Zhang, Xiaoli Gao, Shanrong Han, Na Zheng, Yun Yang, Jingjing Li, Yaqiong Su, Hong Zhang, Ye Li, Wenbing Zhi, Yang Liu
{"title":"Oxysophocarpine Inhibits Apoptosis of Lung Epithelial Cells to Alleviate Acute Lung Injury via KIT/PI3K Signaling Pathway.","authors":"Ziyao Qiao, Kaihua Long, Kairu Ding, Xiaoyan Zhang, Xiaoli Gao, Shanrong Han, Na Zheng, Yun Yang, Jingjing Li, Yaqiong Su, Hong Zhang, Ye Li, Wenbing Zhi, Yang Liu","doi":"10.2147/DDDT.S544479","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Acute lung injury (ALI) is an acute, diffuse, inflammatory lung injury caused by many factors. Oxysophocarpine (OSC), a quinoline alkaloid sourced from traditional Chinese herbs <i>Sophora flavescens</i> and <i>Sophora davidii</i>, possesses anti-inflammatory and antioxidant properties. However, its effects on ALI are still unclear. This study aims to investigate the role and potential mechanisms of OSC for the treatment of ALI.</p><p><strong>Methods: </strong>The levels of TNF-α, IL-6, and IL-1β in bronchoalveolar lavage fluid (BALF) were measured with an enzyme-linked immunosorbent assay (ELISA). Lung tissue changes were examined through hematoxylin and eosin (HE) staining. Lung cell apoptosis was analyzed using the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. Flow cytometry was utilized to detect neutrophil aggregation. Further, the network pharmacology and molecular docking was employed to predict the mechanisms. Key pathways and targets of OSC were confirmed using methods like immunohistochemistry (IHC), immunofluorescence (IF), real-time quantitative PCR (RT-qPCR), and Western blotting (WB).</p><p><strong>Results: </strong>In vivo, OSC treatment significantly inhibited diffuse alveolar injury and interstitial edema compared to the LPS-induced model mice, reduced neutrophil infiltration, and lowered lung epithelial cell apoptosis. In vitro, OSC pretreatment enhanced lung epithelial cell viability and decreased LPS-induced apoptosis. Network pharmacology analysis suggested that OSC mainly targeted key proteins in the PI3K/AKT and apoptosis signaling pathways, such as KIT, PIK3CA, and Bcl-2. Molecular docking confirmed that OSC binds strongly to these targets. Further, PCR, WB, IF, and IHC assay demonstrated that OSC pretreatment elevated PI3K, KIT, and Bcl-2 expressions in BEAS-2B lung epithelial cells and lung tissues.</p><p><strong>Conclusion: </strong>OSC reduced inflammatory cytokine production, neutrophil aggregation, and lung epithelial cell apoptosis via regulating the KIT/PI3K signaling pathway.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"8657-8674"},"PeriodicalIF":5.1000,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476185/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S544479","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: Acute lung injury (ALI) is an acute, diffuse, inflammatory lung injury caused by many factors. Oxysophocarpine (OSC), a quinoline alkaloid sourced from traditional Chinese herbs Sophora flavescens and Sophora davidii, possesses anti-inflammatory and antioxidant properties. However, its effects on ALI are still unclear. This study aims to investigate the role and potential mechanisms of OSC for the treatment of ALI.
Methods: The levels of TNF-α, IL-6, and IL-1β in bronchoalveolar lavage fluid (BALF) were measured with an enzyme-linked immunosorbent assay (ELISA). Lung tissue changes were examined through hematoxylin and eosin (HE) staining. Lung cell apoptosis was analyzed using the terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay. Flow cytometry was utilized to detect neutrophil aggregation. Further, the network pharmacology and molecular docking was employed to predict the mechanisms. Key pathways and targets of OSC were confirmed using methods like immunohistochemistry (IHC), immunofluorescence (IF), real-time quantitative PCR (RT-qPCR), and Western blotting (WB).
Results: In vivo, OSC treatment significantly inhibited diffuse alveolar injury and interstitial edema compared to the LPS-induced model mice, reduced neutrophil infiltration, and lowered lung epithelial cell apoptosis. In vitro, OSC pretreatment enhanced lung epithelial cell viability and decreased LPS-induced apoptosis. Network pharmacology analysis suggested that OSC mainly targeted key proteins in the PI3K/AKT and apoptosis signaling pathways, such as KIT, PIK3CA, and Bcl-2. Molecular docking confirmed that OSC binds strongly to these targets. Further, PCR, WB, IF, and IHC assay demonstrated that OSC pretreatment elevated PI3K, KIT, and Bcl-2 expressions in BEAS-2B lung epithelial cells and lung tissues.
Conclusion: OSC reduced inflammatory cytokine production, neutrophil aggregation, and lung epithelial cell apoptosis via regulating the KIT/PI3K signaling pathway.
期刊介绍:
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.